ABUS vs EXAS · P/E 5.4, rev $6.2M vs rev $2.76B
Arbutus Biopharma Corp (ABUS) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the ABUS and EXAS stock pages for the full models.
Not investment advice.